Elevance Health Inc. Common Stock

Elevance Health Inc. Common Stock Earnings Recaps

ELV Health Care 3 recaps
Next earnings: January 27, 2027 (estimated) · full calendar
Q3 2026 Oct 23, 2026

Elevance raised its 2026 adjusted EPS outlook and set a higher earnings baseline, while projecting at least 12% EPS growth in 2027. Shares fell 1.4%, a broadly flat reaction that tempers the upbeat outlook; the transcript does not identify a specific source of investor disappointment.

Key takeaways
  • 2026 adjusted diluted EPS guidance was raised to at least $29; the company also raised its underlying earnings baseline to at least $26.75, citing better operating results and favorable non-operating items.
  • Management expects at least 12% adjusted EPS growth in 2027, driven by Health Benefits margin improvement, Carelon adoption, and operating efficiency.
  • Medicaid results were ahead of outlook, primarily due to recent rate actions, and the business is tracking slightly ahead of its prior full-year margin guidance.
  • About half of Medicare Advantage members will be in plans rated 4 stars or higher for 2027; management said its plan design and market focus support further margin improvement.
  • Carelon’s commercial cancer care engagement program reduced avoidable inpatient admissions by 15%; its Elevate platform identified more than $300 million in anticipated savings this year.
Q2 2026 Jul 17, 2026

Elevance Health’s stock fell 12.6% as investors reacted negatively to cautious commentary on Medicaid margin pressures and the ongoing strategic exits from underperforming Medicaid markets, signaling concerns about margin compression and deceleration in this key segment despite raised EPS guidance.

Key takeaways
  • The company raised 2026 adjusted EPS guidance to at least $27, supported by disciplined cost management and targeted investments.
  • Medicaid continues to face a dynamic and elevated cost trend environment, with the 2026 operating margin expected to remain at a trough level and margins described as "appropriately prudent and unchanged."
  • Strategic market exits, including the recent decision to leave the D.C. Medicaid market, highlight challenges in generating sustainable returns in Medicaid.
  • Medicare Advantage shows progress due to deliberate repositioning, contributing positively across the portfolio but not enough to offset Medicaid concerns.
  • Investments in AI-enabled care management and digital tools aim to enhance cost detection and clinical intervention but remain future-oriented with uncertain impact on near-term results.
Q1 2026 Apr 22, 2026

Elevance Health delivered a strong first quarter, exceeding expectations through solid business performance, strategic realignment, and advanced AI integration, prompting a raised full-year EPS guidance of at least $26.75.

Key takeaways
  • First quarter results benefited from improved claims experience, ACA seasonality, and nonrecurring investment income.
  • Strategic initiatives—including leadership realignment and scaling AI—are enhancing operational efficiency and clinical outcomes.
  • Carelon’s integrated, risk-based solutions reduced hospital readmissions by 20% and achieved over 10% savings on post-acute care.
  • Progress in Medicaid and Medicare Advantage management supports mid-single-digit operating margins, with ongoing focus on risk adjustment and long-term value.
  • Commercial and individual ACA businesses show disciplined pricing and modest retention improvements, bolstering future growth prospects.